Results of Prostvac PROSPECT trial scheduled for later in 2017

According to Barvarian Nordic, the key results of the Phase III clinical trial of the immunologic agent Prostvac (rilimogene galvacirepvec/rilimogene glafolivec, or “rilimogene”) in treatment of metastatic, castration-resistant prostate cancer (mCRPC) are now expected in the second half of 2017. … READ MORE …

Prostvac VF: a clinical trials update

The Phase III clinical trial of Prostvac VF (rilimogene galvacirepvec/rilimogene glafolivec) in treatment of metastatic, castration-resistant prostate cancer is now fully enrolled, and initial results of this critical trial are expected within the next 12 months. However, … READ MORE …